science
European Commission Grants Marketing Authorization for Moderna's MCOMBRIAX Vaccine
Moderna has received marketing authorization from the European Commission for MCOMBRIAX, its mRNA combination vaccine against influenza and COVID-19. This enables distribution in European markets. The vaccine targets respiratory viruses with combined protection.
FI
Substrate placeholder — needs reviewAudio version
Tap play to generate a narrated version.
Developing·Limited corroboration so far. This page will refresh as more sources emerge.
The European Commission has granted marketing authorization for MCOMBRIAX, Moderna's mRNA combination vaccine against influenza and COVID-19, @FirstSquawk reported. Moderna received the authorization, which allows the company to distribute MCOMBRIAX in European markets. MCOMBRIAX is an mRNA combination vaccine developed by Moderna to combat both influenza and COVID-19.
The authorization represents progress in efforts to address respiratory viruses through combined vaccination.
Transparency
1 source · single source
CorroborationModerate · 1 source
